Scientists have identified a genetic explanation for why some people fail to lose weight on blockbuster drugs like Ozempic and Wegovy, despite the medications working spectacularly for millions of others.
Roughly 10% of users experience what researchers are calling "GLP-1 resistance," a condition where their bodies produce unusually high levels of the hormone these drugs are designed to target, yet show little to no response to the medication.
The finding, detailed in a new study, suggests that certain genetic variants prevent the drugs from working as intended in a meaningful portion of the population. For these individuals, the medications fail to suppress appetite or drive weight loss the way they do for typical users.
GLP-1 receptor agonists like Ozempic and Wegovy have become among the most sought-after medications in recent years, with celebrities and everyday Americans alike crediting them with dramatic weight loss. The drugs work by mimicking glucagon-like peptide-1, a natural hormone that regulates blood sugar and appetite.
But the new research exposes a blind spot in how these medications perform across different genetic backgrounds. People with GLP-1 resistance produce elevated levels of the hormone itself, yet their bodies fail to respond appropriately to either the natural version or the drug-delivered version.
The discovery could eventually lead to genetic testing before prescription, allowing doctors to identify who will benefit from the drugs and who might need alternative treatments. For now, it underscores that even breakthrough medications have limits, and not everyone's biology cooperates with pharmaceutical success stories.
Comments